Several mutant mouse models for human diseases such as diabetes mellitus have been 28 generated in the large-scale Munich ENU (N-ethyl-N-nitrosourea) mouse mutagenesis project. 29
Introduction 51
The catalytic enzyme glucokinase is one of the four members of the hexokinase family but its 52 kinetic differs from those of the other hexokinases, due to a lower affinity for glucose, the 53 lack of physiologically relevant direct feedback inhibition by its product glucose-6-phosphate 54 (G6P), and its sigmoidal kinetics (34) (35) . Since glucokinase catalyses the first rate-limiting 55 step of glycolysis -the phosphorylation of glucose to G6P -it is considered as a "glucose 56 sensor". Mutations in the glucokinase gene (GCK) can cause hyperglycemia as well as 57 hypoglycemia (19) . Homozygous inactivating mutations in the human GCK are associated 58 with permanent neonatal diabetes mellitus (PNDM), whereas heterozygous inactivating 59 mutations lead to maturity-onset diabetes of the young, type 2 (MODY 2), a well known 60 specific form of diabetes (3, 22) . 61 MODY, representing a genetically and clinically heterogeneous group of diabetes subtypes, is 62 characterized by an autosomal dominant mode of inheritance (22), early onset of 63 hyperglycemia due to defects in β-cell function and disturbed insulin secretion, whereas 64 insulin action usually is not impaired (3). In contrast to other MODY subtypes, like MODY 1 65 and 3 (61), MODY 2 is characterized by mild, but chronic hyperglycemia, which may 66 deteriorate little with age, but usually remains considerably stable, due to compensatory 67 mechanisms, as, for instance, overexpression of the wild-type allele (22) . Despite being 68 present form birth, the diabetic phenotype often remains undiagnosed, because the occurrence 69 of the disease varies, depending on the severity of glucokinase impairment, from 70 asymptomatic mild hyperglycemia, over various degrees of glucose intolerance up to the 71 development of persistent fasting hyperglycemia (15, 61) . Even if some MODY 2 patients 72 display peripheral insulin resistance, this phenomenon might be secondary to the disease 73 rather than a direct consequence of the mutation (11). Since development of overt diabetes is 74 7 minutes. Further, 20 mg freshly isolated liver tissue was homogenized in 1 ml buffer (20) , 149 using a Polytron PT 1200 E tissue homogenizer (Kinematica AG, Luzern, Switzerland) and 150 then sonicated. Hepatic glucose phosphorylating activity was determined in the presence of 151 either high (100, 50, 25, 12 , and 6 mM) or low (0.5, 0.25, 0.125, 0.06, and 0.03 mM) glucose 152 concentrations after incubation for 30 minutes at 30°C. Fluorescence was determined using a 153 SPEKOL 1500 UV/vis spectrophotometer (Analytic Jena AG, Jena, Germany). Glucokinase 154 activity was corrected for the hexokinase fraction by subtracting the activity at 0.50 mM 155 glucose from total activity observed in the presence of high glucose concentrations, and 156 referred to the total protein content in the homogenate, determined by the Bradford method. 157
158

Quantitative real-time PCR
159
Total RNA from isolated pancreatic islets was purified, using the RNeasy-Mini Kit (Qiagen, 160 Hilden, Germany). Each 400 ng of total hepatic RNA isolated from liver homogenates of 161 newborn and 85-day-old mice and each 400 ng of total islet RNA from 85-day-old mice were 162 reverse transcribed as described above. cDNA-specific primers for amplification of mouse 163
Gck (sequences are listed in Table 1 Supporting Material), and the house-keeping genes β-164 actin (Actb) (41), mitochondrial ribosomal protein S9 (Mrps9) (25), and 18S ribosomal RNA 165 (18s rRNA) (51) were chosen, using Primer Express version 3.0 (Applied Biosystems), and 166 queried by NCBI Blast software (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Real-time PCR 167 analyses were performed as previously described (25) TrisHCl pH 7.6, 0.5% Ipegal CA 630, 250 mmol/l NaCl, 3mmol/l EDTA, 3mmol/l EGTA, 176 1mmol/l phenymethylsulfonyl fluoride (PMSF), 2mmol/l Na-orthovanadate, 1mmol/l DTT 177 (dithiothreitol) and sonicated. Islet and liver homogenate was centrifuged (10 minutes 10.000 178 rpm) and protein content in the supernatant was quantified by Bradford method. Twenty μg 179 total islet and liver protein was subjected to SDS-Page and transferred on a nitrocellulose 180 membrane (Schleicher&Schüll, Dassel, Germany) . Following primary antibodies were used: 181 rabbit anti-glucokinase (1:250) (Abcam, Cambridge, MA, USA) and mouse anti-actin 182
(1:10,000) (Cell Signaling Technology, Beverly, MA, USA). Peroxidase conjugated goat anti-183 rabbit IgG (Cell Signaling Technolgy) and rabbit anti-mouse Ig (Dako Diagnostika, Hamburg, 184 Germany) diluted 1:10,000 were used as secondary antibodies. Further, a rabbit anti caspase-3 185 antibody (Cell Signaling Technology) was applied to detect the inactive and induced form of 186 caspase-3 in pancreatic islets as an indicator of apoptosis (1:1,000). The specific bands were 187 visualized by chemiluminescence (Luminol, Santa Cruz Technology, Inc, Santa Cruz, CA, 188 USA) and quantified by densitometry using the ImageJ software (Rasband, W.S., ImageJ, U. 189 S. National Institutes of Health, Bethesda, Maryland, USA, http://rsbweb.nih.gov/ij/). 190
191
Body weights and glucose homeostasis
192
The body weight of mice was first determined at the day of birth and at an age of 4 days. The 193 body weight of ad libitum fed 21-, 85-, and 170-day-old mice was determined to the nearest 194 of 0.1 g. The body weight of fasted mice was also quantified at an age of 30, 90 and 180 days. 195 Blood glucose concentrations of ad libitum fed and fasted animals were determined at the 196 indicated age, using the GLeasy system (Dr. Müller Gerätebau, Freital, Germany).
9
Oral glucose tolerance tests (OGTT) were performed in 30-, 90-, and 180-day-old 198 heterozygous mutants and wild-type littermate controls as previously described (24 were carried out, using unbiased model-independent methods (21, 64) as previously 217 described. Briefly, the pancreas volume (V (pan) ) was calculated dividing the pancreas weight 218 by the specific weight of mouse pancreas (1.08 mg/mm 3 ). The volume density of islets in the 219 pancreas (Vv (islets/pan) ) was calculated dividing the sum of cross-sectional areas (Σ A) of islet 220 profiles by the Σ A of the pancreas. The total islet volume (V (islets, pan) ) was calculated by 221 multiplying Vv (islets/pan) and V (Pan) . The volume density of β-cells in the islets (Vv (β-cells/islets) ) 222 was obtained by dividing Σ A β-cells and Σ A islets; the total β-cell volume (V (β-cells, pan) ) was 223 attained by multiplying Vv (β-cells/islets) and V (islets, pan) (23) (24) . Additionally, the volume density 224 of the β-cells (Vv (β-cells/pan) ) in the pancreas of newborn male mice was calculated by dividing 225 sum of cross sectional areas of β-cells by Σ A of the pancreas. The total β-cell volume (V (β-226 cells, pan) ) was determined by multiplying Vv (β-cells/pan) and V (pan) . Inheritance of the abnormal phenotype was tested as previously described (2). After 251 confirmation of an autosomal dominant inheritance of the diabetic phenotype, male 252 hyperglycemic mice were mated to wild-type C3H females to establish the mutant strain 253
GLS001. 254 255
Linkage analysis, candidate gene sequencing, and genotyping
256
The SNP analysis, using a genome-wide mapping panel comprising a total number of 136 257 polymorphic markers, revealed a strong linkage (χ 2 =64.66; p<0.0001) of the diabetic 258 phenotype to the marker rs13480881, localized at the proximal region of chromosome 11. 259
Sequencing of the positional candidate gene Gck disclosed a T→G transversion at nucleotide 260 position 629 in exon 6 of Gck (NCBI GeneBank accession no. NM_010292) (Fig. 1A, B) . 261
The probability of an additional confounding ENU-induced mutation between the two 262 polymorphic markers with the highest linkage as well as within the region upstream of the 263 polymorphic marker with the highest linkage was 0.0006 and 0.0045, respectively 264 (http://zeon.well.ox.ac.uk/git-bin/enuMutRat). The mutation leads to an amino acid exchange 265 from methionine to arginine at position 210. According to the mutation, the official term 266
Munich Gck M210R mutant mouse was chosen for this hyperglycemic strain. The single base 267 pair substitution from T to G creates a new restriction site for the enzyme BstYI. Hence, 268 differentiation of the allelic genotype was feasible using RFLP-based strategies (Fig. 1C) . 269
270
Glucokinase enzyme activity
271
The fluorometric coupled assay carried out with liver homogenate showed a significantly 272 reduced hepatic glucokinase phosphorylating activity in heterozygous Munich Gck mutants (by about 50% vs. wild-type mice) ( Fig. 1D , E), whereas islet glucokinase activity 274 and hepatic and islet hexokinase activities were not significantly altered. Nevertheless, in 275 pancreatic islets, low glucose affinity hexokinase activity was about 6-fold higher than 276 glucokinase activity, whereas in liver, hexokinase activity contributed only to a minor extend 277 to the total hepatic phosphorylating activity (Fig. 1E, F) . 278
279
Quantitative real-time PCR
280
The relative Gck transcript abundance in liver homogenates from newborn mice was 281 significantly reduced in both homozyogous and heterozygous mutants vs. wild-type mice and 282 in homozyogous vs. heterozygous mutants (Fig. 1G ). In contrast, at an age of 85 days, relative 283
Gck transcript abundance of heterozygous mutants was unchanged in liver homogenate (Fig. 284 1H) and in pancreatic islets ( Fig. 1I) Heterozygous mutants showed slightly, but significantly elevated ad libitum fed blood 294 glucose levels from the first days of life onwards ( Fig. 2A, B) . Disturbance in glucose 295 homeostasis of these mutants deteriorated little until 85 days of age, remaining stable 296 thenceforth ( Fig. 2C ). At 30 days of age, fasting blood glucose levels were found to be 297 significantly elevated in both heterozygous male and female mutants, and remained stable 298 during the period investigated (Fig. 2D) . 299
During OGTT, 30-day-old male and female heterozygous mutants showed significantly 300 elevated blood glucose levels until 90 minutes after oral glucose application. At 120 minutes, 301 blood glucose concentrations of heterozygous mutants were similar to those of wild-type mice 302 (Fig. 3A) . At an age of 90 and 180 days, blood glucose concentrations of heterozygous 303 mutants were significantly increased at all time points during OGTT as compared to age-and 304 sex-matched wild-type animals ( Fig 3B; Table 2 Supporting Material). The area under the 305 glucose curve (AUC) was already significantly increased in 30-day-old heterozygous mutants 306 of both sexes, and further deteriorated with age, while the AUC of wild-type mice remained 307 almost constant until an age of 180 days (Fig. 3C) . 308
Fasting serum insulin levels were significantly decreased in 90-and 180-day-old male 309 heterozygous mutants, and both genders of all examined age-groups displayed significantly 310 reduced insulin secretion after oral glucose administration (Fig. 3D, E) . During OGTT, 311 performed with 90-day-old mice, serum insulin levels were significantly reduced until 30 312 minutes after oral glucose application in male and until 10 minutes in female mutants. 313
Furthermore, male heterozygous mutants exhibited a significantly decreased area under the 314 14 insulin curve during OGTT at an age of 90 days, whereas the AUC insulin was only slightly 315 reduced in female mutants (Fig. 3F) . Consequently, the HOMA of β-cell function index was 316 reduced by about 75% in male and female heterozygous mutants as compared to sex-matched 317 controls (Fig. 3G) . 318
At an age of 30 days, blood glucose decrease during ITT was comparable between 319 heterozygous mutants and wild-type mice (Supporting Material Table 3A ), while 85-and 320 170-day-old male mutants showed a significantly less pronounced decrease of blood glucose 321 levels from basal, 10 minutes after intraperitoneal insulin application vs. male controls (Fig.  322 3H; Supporting Material Table 3B ). However, the HOMA of insulin resistance index of male 323 mutants was not altered (Fig. 3I) . 324 325
Clinically relevant parameters in homozygous mutants
326
Homozygous mutants were born as expected according to the Mendelian pattern of 327 inheritance. Already at the first day post partum, homozygous mutants showed marked 328 glucosuria and dramatically elevated blood glucose concentrations with severe deterioration 329 of the diabetic phenotype until an age of 4 days ( Fig. 2A, B) . The birth weight of homozygous 330 mutants was not different as compared to heterozygous mutants and wild-type controls (Fig.  331   4A ), but did not increase during the first days of life. At an age of 4 days, the body weight of 332 homozygous mutants was less than 50% than that of age-matched controls (Fig. 4B) . 333
Homozygous mutants died of severe diabetes mellitus, not later than 6 days post partum. The 334 mean survival period of homozygous mutants was about 4 days whereas live expectancy of 335 heterozygous mutants in relation to wild-type animals was not constrained (Fig. 4C, D) . for any inflammatory event in the islets was detectable. Insulin-immunostaining of pancreas 342 sections from these mutants revealed typical islet composition and distribution of insulin 343 positive cells within the islets. β-cell staining intensity for insulin was also comparable to 344 control mice (Fig. 5A-E density of islets in the pancreas (Vv (islets/pan) ), the total islet volume (V (islets,pan) ), and the total β-350 cell volume (V (β-cells, islets) ) of heterozygous male but not of female mutants was significantly 351 decreased vs. age-and sex-matched controls (Fig. 6D, G, H) . Additionally, the volume 352 density of isolated β-cells in the pancreas (Vv (isolated β-cells/pan) ) and the total volume of isolated 353 β-cells (V (isolated β-cells,pan) ) were significantly decreased in 210-day-old male heterozygous 354 mutants (Fig. 6 F, I ). Combined TUNEL/insulin immunostaining of pancreas sections of 210-355 day-old male mice could not demonstrate any apoptotic β-cells in the investigated islets of 356 wild-type mice and heterozygous mutants, whereas occasional apoptotic cells were observed 357 in the exocrine pancreas and lymph nodes. The pancreatic insulin content of 270-day-old male 358 heterozygous mutants was only marginally reduced as compared to wild-type mice (Fig. 5H) . Breeding heterozygous mutants to C3H wild-type mice over more than ten generations led to 365 the loss of non-causative, clinically unapparent ENU-induced mutations. The occurrence of 366 the diabetic phenotype remained unaltered in ensuing generations, giving proof of the 367 heritability and the complete penetrance of the abnormal phenotype. Together with the 368 linkage analysis carried out, these findings indicate that the identified missense mutation in 369 the glucokinase gene is causative for the diabetic phenotype of the mouse strain. 370
The catalytic enzyme glucokinase is known to play a central role in glucose homeostasis. In 371 hepatocytes, glucokinase facilitates glucose uptake and controls glycogen synthesis (46), 372 whereas in pancreatic β-cells, it catalyses the first, rate-limiting step of glycolysis, and is 373 therefore considered as a "glucose sensor" (19, 35). Hence, already minimal changes in 374 glucokinase enzyme activity can entail serious consequences for the organism, because the 375 threshold for glucose-induced insulin secretion is directly altered (46). 376
Various Gck-deficient mouse models have already been generated (6, 20, (46) (47) 55 For the majority of ENU-induced Gck mutant strains, the mutation was found to result in 388 significantly reduced glucokinase activity (27, 57) and the human M210K mutation was also 389
shown to be associated with reduced enzyme activity in vitro (39). Likewise, hepatic 390 glucokinase activity was decreased in heterozygous Munich Gck M210R mutants, demonstrating 391 that the identified mutation is causative for the diabetic phenotype. The fact that islet 392 glucokinase activity in heterozygous mutants was obviously unaffected might be caused by 393 the predominance of low affinity hexokinase activity in pancreatic islets which probably 394 impedes the identification of potential differences of islet glucokinase activity (58). 395
Additionally, the mutation leads to a significant reduction of hepatic Gck expression in 396 newborn homozygous and heterozygous Munich Gck M210R mutants. In adult heterozygous 397 mutants, hepatic Gck and islet Gck mRNA levels were unaltered, most likely as a 398 consequence of efficient compensatory mechanisms, such as overexpression of the wild-type 399 allele (59). The initial decrease of hepatic Gck transcript abundance in neonatal mutants might 400 reflect the lack of compensatory overexpression of the wild-type allele at this age. Consistent 401 with these findings, hepatic glucokinase protein levels were only slightly reduced, and islet 402 glucokinase protein abundance was unaltered in heterozygous mutants as compared to wild-403 type littermates. The mutation M210K has already been shown to be refractory to glucokinase 404 activators as well as to increasing concentrations of glucokinase regulatory protein (GKRP), 405 which is known to be critically involved in post-transcriptional and -translational regulation of 406 hepatic glucokinase. Therefore, impaired interaction with GKRP might account for the 407 marginal reduction of hepatic glucokinase protein abundances in Munich Gck M210R mutants 408 (8, 16, 52) . Reduction of Gck expression and glucokinase protein levels have also been 409 reported to be a consequence of glucokinase mutations in ENU-induced mutants (27, 57) . 410
Since in heterozygous mutants glucokinase activity was reduced to 50% of the wild-type 411 catalytic enzyme activity, they exhibited slightly elevated blood glucose levels already from 412 birth with development of glucose intolerance and stable fasting hyperglycemia from 30 days 413 of age. In contrast, homozygous mutants showed severe hyperglycemia at the first day of life 414 with a dramatically increase of blood glucose levels within one day, suggesting glucokinase 415 activity to be drastically reduced in these animals. The exacerbated phenotype of homozygous 416 mutants resembles that of PNDM in humans, where a homozygous M210 mutation has also 417 been identified (39) (40) . 418
Similar to clinical findings in MODY 2 patients (22), hyperglycemia in heterozygous mutants 419 was chronic, but mild with slight deterioration of blood glucose concentrations until an age of 420 85 days, followed by stabilization of the diabetic phenotype. Due to this lenient and stable 421 phenotype, life expectancy was not reduced in heterozygous mutants, whereas the mutation is 422 lethal soon after birth, when present on both alleles. A comparable limitation of life 423 expectancy was observed in other homozygous murine glucokinase mutants (27) as well as in 424 homozygous global and β-cell-specific Gck knockout mice (6, 20, (46) (47) 55) existing β-cells are reported to be the main mechanisms of these adaptive changes (1, 10, 45) . 473
For one of these mechanisms, glucokinase has already been shown to be essential: mice, 474 haploinsufficient for pancreatic Gck, failed to increase β-cell mass in response to a high-fat 475 diet, whereas wild-type controls developed compensatory β-cell hyperplasia. However, in 476 contrast to Munich Gck M210R mutant mice, no reduction of β-cell mass or islet size was 477 detected in β-cell-specific heterozygous Gck knockout mice vs. wild-type mice, when fed a 478 standard chow (56). As the genetic background has a great influence on the occurrence of an 479 aberrant phenotype (5), these different observations might be explained by the different 480 genetic background of the Gck mutants. Additionally, parameters of islet neogenesis and the 481 influence of complete absence of β-cell glucokinase on the integrity of the endocrine pancreas 482
were not investigated in these knockout models. Bernard C, Berthault MF, Saulnier C, and Ktorza A. 
